Results of a Multicenter, Randomized, Double-Blind, Phase III Study of TAS-102 vs. Placebo, with Best Supportive Care (BSC), in Patients (PTS) with Metastatic Colorectal Cancer (MCRC) Refractory to Standard Therapies (RECOURSE)

on behalf of the RECOURSE Study Group

Research output: Contribution to journalArticlepeer-review

Original languageEnglish
Pages (from-to)ii114
JournalAnnals of Oncology
Publication statusPublished - Jun 2014

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this